A LinkedIn post from Forge Biologics highlights an open Scientist II role in upstream process development focused on adeno-associated virus, or AAV, gene therapy manufacturing for client programs. The post describes responsibilities including leading complex experiments, driving scale-up strategies, supporting tech transfer and validation, and enabling cGMP execution across functions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The posting suggests Forge is investing in senior technical talent to strengthen its development-to-manufacturing capabilities, which could support higher-value service offerings and improved execution for partners. For investors, the emphasis on upstream process expertise and scalable manufacturing may indicate preparation for increased client demand and a focus on building differentiated competence in AAV gene therapy production within the contract development and manufacturing space.